Jaw Reduction — Cost, Top Hospitals & Success Rates | MyMedicPlus

Jaw reduction, also called mandibular angle reduction or V-line surgery, is a facial contouring procedure designed to narrow or reshape the lower jaw and create a more oval or tapered facial appearance. It addresses an overly wide, square, or prominent mandible — a concern that may be structural (bony prominence) or functional (enlarged masseter muscles).

The procedure has deep roots in East and Southeast Asian aesthetic surgery, particularly in South Korea, where V-line facial contouring has been refined over decades. However, it is also performed globally for functional indications such as bruxism-related masseter hypertrophy and post-traumatic jaw asymmetry.

Jaw reduction can be achieved through two principal approaches:

• Surgical osteotomy: The surgeon reshapes or removes portions of the mandibular angle and body using bone-cutting instruments, accessed via small incisions inside the mouth (intraoral approach), leaving no visible external scars.
• Masseter reduction with botulinum toxin (Botox): Injections into the masseter muscle cause controlled muscle atrophy, reducing the bulk of a hypertrophied masseter without surgery. This is a non-invasive, reversible option.

Selecting the right technique requires a thorough evaluation of bony anatomy (via CT or panoramic X-ray), soft tissue thickness, occlusion, and the patient's aesthetic goals. A board-certified maxillofacial or craniofacial surgeon should perform the assessment.

Jaw reduction is indicated for both aesthetic and medical conditions affecting the lower jaw:

• Mandibular prognathism (square jaw): A genetically wide or protruding jaw that creates an overly angular facial profile.
• Masseter hypertrophy: Enlargement of the masseter muscles — often from bruxism (teeth grinding), habitual chewing of tough foods, or hereditary factors — produces a bulky, square lower face.
• Facial asymmetry: Unequal jaw angles on left and right sides can be corrected with targeted contouring.
• Post-traumatic mandibular deformity: Fractures or previous surgeries may leave the jaw asymmetric or prominent.
• Bruxism-related pain: Masseter Botox reduces the force of clenching and can relieve associated temporomandibular joint (TMJ) discomfort and headaches.
• Gender-affirming facial surgery: Jaw reduction is a key component of feminisation rhinoplasty (FFS) protocols, softening a typically more angular masculine jaw.

Candidates for jaw reduction are evaluated against the following criteria:

• Age: Surgical candidates should be at least 20–22 years old, ensuring skeletal maturity (the mandible continues to develop into the early twenties). Botox injections may be used earlier for masseter hypertrophy but are generally deferred until adulthood.
• Bone assessment: Imaging (panoramic radiograph or cone-beam CT) is performed to assess mandibular cortex thickness, inferior alveolar nerve position, and degree of bone flaring before surgery is planned.
• Dental occlusion: Patients must have a stable bite. Those with significant malocclusion may require orthodontic preparation or combined orthognathic surgery first.
• General health: Standard surgical fitness criteria apply — no active infection, controlled systemic diseases, normal clotting function.
• Psychological readiness: Realistic expectations and a clear understanding of the limits of improvement are essential. Psychological screening is recommended for patients with body dysmorphic tendencies.
• Non-surgical candidates: Patients whose jawline bulk is predominantly muscular rather than bony are ideal for Botox masseter reduction with minimal downtime.

Patients who smoke are strongly advised to cease at least four weeks before and after surgery to reduce infection risk and optimise healing.

Several techniques are available depending on the underlying anatomy and desired outcome:

• Intraoral mandibular angle osteotomy: The gold-standard surgical technique. Through a small incision inside the mouth, the surgeon uses an oscillating saw or burr to remove or reshape the outer cortex and angle of the mandible. The intraoral approach avoids any external facial scars. Operating time is typically 2–3 hours under general anaesthesia.
• Long-curve osteotomy (extended angle reduction): A more aggressive technique that contours a broader segment of the mandibular body — from the angle forward toward the chin — for a more pronounced V-line effect. Requires precise nerve mapping to protect the inferior alveolar nerve.
• Outer cortex grinding (bone burring): Rather than removing full bony segments, the outer cortical layer is ground down to reduce overall jaw width. Lower risk of fracture, suitable for moderate prominences.
• Botulinum toxin (Botox) injection: 25–50 units of botulinum toxin type A are injected bilaterally into the masseter muscles. Visible slimming begins within 4–8 weeks as the muscle atrophies. Effects last 4–6 months; repeated injections over 2–3 years can produce lasting atrophy. No anaesthesia or downtime required.
• Combined approach: Some patients with both bony prominence and masseter hypertrophy benefit most from surgical osteotomy combined with post-operative Botox maintenance injections.
• Genioplasty (chin augmentation or reduction): Frequently performed alongside jaw reduction to optimise lower facial balance, particularly when a V-line outcome is desired.

Jaw reduction offers measurable functional and aesthetic benefits:

• Permanent structural change: Surgical osteotomy produces a permanent reduction in jaw width — results do not revert with age or weight change.
• Improved facial harmony: By reducing jaw width, the mid-face (cheekbones) becomes relatively more prominent, and the overall facial oval appears more balanced and proportionate.
• No external scarring: The intraoral approach leaves all incisions inside the mouth, making the procedure scar-free externally.
• TMJ and bruxism relief: Masseter Botox significantly reduces clenching force and alleviates associated TMJ pain, headaches, and tooth wear. Multiple studies support its efficacy for bruxism management.
• Short procedure time: Surgical jaw reduction typically takes 2–4 hours; Botox injections take under 15 minutes in an office setting.
• Minimal visible downtime for Botox: Non-surgical masseter reduction causes only minor injection-site tenderness, allowing patients to return to normal activities the same day.
• Gender-affirming outcomes: Jaw feminisation contributes significantly to a patient's sense of congruence and wellbeing in facial feminisation surgery protocols.

As with all surgical procedures, jaw reduction carries potential risks that patients should discuss thoroughly with their surgeon:

• Inferior alveolar nerve injury: The nerve running through the mandible supplies sensation to the lower lip, chin, and teeth. Temporary numbness is common post-operatively; permanent numbness or paraesthesia occurs in fewer than 1–2% of cases in experienced hands.
• Asymmetry: Minor differences between the two sides are possible. Revision surgery is occasionally required to address significant asymmetry.
• Bone fracture: Overly aggressive osteotomy or bone thinning can lead to inadvertent fracture of the mandible, requiring fixation plates.
• Infection: Intraoral incisions are in a non-sterile environment. Strict antibiotic prophylaxis is standard; overt infection requiring drainage is uncommon (<1%).
• Swelling and prolonged oedema: Facial swelling peaks in the first 2–3 days and resolves gradually over 3–6 months. Some residual firmness in the soft tissues may persist for up to a year.
• Haematoma: Blood pooling under the skin or mucosa may require drainage.
• Sagging soft tissues (jowling): When a significant amount of bone is removed, overlying soft tissue may appear slightly loose — a risk most pronounced in older patients or when combined with significant weight loss.
• Botox-specific risks: Inadvertent spread of toxin may weaken nearby smile muscles (zygomaticus) transiently. This resolves within a few weeks. Results are entirely reversible.

Recovery from surgical jaw reduction follows a predictable timeline:

• Days 1–3: Significant swelling and bruising of the lower face; ice packs and head elevation are recommended. A liquid diet is mandatory. Oral rinses with chlorhexidine prevent surgical site infection.
• Week 1–2: Swelling begins to subside; patients may feel the reduced jawline beneath the oedema. Dissolvable sutures begin to absorb. Most patients take 1–2 weeks off work.
• Weeks 2–6: A soft diet (avoiding hard, crunchy, or chewy foods) must be maintained to protect the healing bone. Gentle mouth opening exercises help prevent trismus (jaw stiffness).
• Months 2–3: Approximately 70–80% of swelling has resolved. The new jaw contour becomes increasingly visible.
• Months 3–6: Residual deep tissue swelling continues to fade. Final results are typically apparent at 6–9 months post-surgery.

Follow-up appointments are typically scheduled at 1 week, 1 month, 3 months, and 6 months. Panoramic X-rays at 3–6 months confirm adequate bone healing. For Botox patients, a review at 4–6 weeks assesses muscle response and determines whether a touch-up dose is needed.

The cost of jaw reduction varies substantially based on technique, location, and provider expertise:

• Surgical jaw reduction (intraoral osteotomy): USD 5,000–15,000 in South Korea and Southeast Asia (Thailand, Malaysia); USD 12,000–25,000 in the United States; USD 8,000–18,000 in the United Kingdom.
• Botox masseter reduction: USD 300–800 per session (bilateral); sessions required every 4–6 months initially, with frequency reducing over time.
• Additional costs: Pre-operative imaging (CT/panoramic X-ray), anaesthesiology fees, hospital facility charges, post-operative medications, and any revision procedures are typically billed separately.
• Medical tourism: South Korea (particularly Seoul's Gangnam district) is the leading destination for jaw reduction surgery, with highly experienced craniofacial surgeons and competitive pricing. Thailand and India offer lower-cost alternatives with internationally accredited facilities.

Most health insurance plans classify jaw reduction as a cosmetic procedure and do not provide coverage. Exceptions may apply where the procedure is medically indicated — for example, severe bruxism-related TMJ dysfunction or post-traumatic reconstruction. Always confirm coverage in writing before proceeding.

For patients who are not candidates for surgery, or who prefer non-invasive options, the following alternatives can achieve partial facial slimming:

• Botulinum toxin (Botox): The primary non-surgical alternative for masseter hypertrophy. Safe, repeatable, and reversible. Effective for muscle-driven jaw width but cannot alter underlying bone.
• Dermal fillers for facial balancing: Strategic placement of hyaluronic acid fillers in the temples, cheeks, and chin can create the visual impression of a slimmer lower face without reducing the jaw directly.
• Orthodontics and splint therapy: For patients with bruxism, custom occlusal splints reduce clenching forces and may over time modestly reduce masseter bulk, though far less dramatically than Botox.
• Weight management and diet: Reducing facial fat through overall weight management can soften the lower facial contour, though it does not address bony or muscular prominence.
• Contouring make-up: Non-medical jawline slimming through make-up contouring — a reversible, zero-risk option for those seeking purely cosmetic change without any intervention.